#USA #Veeva Systems #Barcelona #Clinical Trial #Amgen

Veeva Collaborates with Amgen to Enhance Clinical Trials

In a bold move to reshape the landscape of clinical trials, Veeva Systems (NYSE: VEEV) has formally announced its partnership with Amgen, one of the leaders in global biotechnology. This collaboration aims to leverage Veeva's Clinical Platform to significantly streamline and improve the efficiency of the clinical trial process. With the increasing complexity of clinical trials and the urgent need for faster drug development, this partnership represents a strategic effort to push the boundaries of innovation in healthcare.

Scott Skellenger, Senior Vice President and Chief Information Officer at Amgen, emphasized the importance of utilizing advanced technology in their clinical operations. He stated, "We are leveraging advanced technology to develop new capabilities in our end-to-end clinical trial operations, which we expect will further strengthen our ability to deliver innovative treatments to patients quickly and at scale."

The Veeva Clinical Platform is a comprehensive and interconnected solution that integrates clinical operations and data applications. It encompasses various tools designed for clinical trial management systems (CTMS), electronic data capture (EDC), interactive response technology (RTS), electronic clinical outcome assessment (eCOA), electronic trial master file (eTMF), and more. By optimizing the entire trial process from start to finish, Veeva aims to create a cohesive data flow that accelerates essential medical deliveries to patients who require them.

Jim Reilly, President of Veeva Development Cloud, expressed his excitement about the partnership’s potential, saying, "We are thrilled to assist Amgen in furthering clinical development. The Veeva Clinical Platform will lay the groundwork for standardized and interconnected processes that can hasten the delivery of vital drugs to patients in need."

As part of the collaboration, Veeva Business Consulting will provide support to Amgen throughout the implementation phase and assist with change management, ensuring that the transition to the new platform is as seamless as possible.

About Veeva Clinical Platform

The Veeva Clinical Platform is designed to address the modern challenges faced in clinical trials by integrating disparate clinical operations and data management into one unified system. This interconnected platform includes essential components like CTMS, EDC, Clinical Workbench (CDB), RTSM, eCOA, eTMF, and Study Training, among others, allowing biopharmaceutical companies to optimize their workflows and improve data accuracy while also enhancing collaboration across global teams.

Veeva's commitment to innovation and excellence is reflected in its service to over 1,500 clients, ranging from the world's largest biopharmaceutical companies to emerging biotech firms. The company operates with a clear mission to balance stakeholder interests, including customers, employees, investors, and the broader industries it serves.

Conclusion

As Veeva and Amgen embark on this ambitious partnership, the future of clinical trials looks promising. This collaboration not only signifies a technological advancement in the biopharmaceutical sector but also highlights the essential role of innovation in developing treatments for serious medical conditions. As the pharmaceutical industry continues to evolve, strategic partnerships like this will likely play a crucial role in accelerating drug development and delivering breakthroughs to patients more effectively than ever before.